Global specialist law firm Dechert LLP advised Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL), a Danish biotechnology company with leading expertise in the discovery, design and development of novel peptide therapeutics, on its second collaboration with Boehringer Ingelheim GmbH, a privately-held German-based pharmaceutical company. The new agreement covers a global exclusive license and a research and development collaboration on one specific novel therapeutic peptide project from Zealand’s portfolio of preclinical programs and aims to develop novel medicines for improved treatment of patients with cardio-metabolic diseases. The biological target is undisclosed.

The Dechert team advising Zealand on the new collaboration agreement includes partners Jonathan Schur and Kristopher Brown (Corporate) and Thomas Rayski (Intellectual Property).

The firm also advised Zealand on its first global license agreement with Boehringer Ingelheim in 2011, which is ongoing, to develop new compounds to treat type 2 diabetes and obesity, as well as its 2010 initial public offering and other transactions.